Celldex Tests Its Brain Tumor Vaccine in Multicenter Trial
Celldex Therapeutics has initiated a multicenter phase II/III trial of its brain tumor vaccine CDX-110 in patients with newly diagnosed glioblastoma multiforme (GBM) that expresses EGFRvIII, a variant of EGFR not present in normal tissue.
PHILLIPSBURG, New JerseyCelldex Therapeutics has initiated a multicenter phase II/III trial of its brain tumor vaccine CDX-110 in patients with newly diagnosed glioblastoma multiforme (GBM) that expresses EGFRvIII, a variant of EGFR not present in normal tissue. Participants at 20 sites will be randomized to standard of care maintenance chemotherapy with temozolomide (Temodar) alone or with biweekly to monthly intradermal injections of CDX-110 continuing until disease progression. In previous trials, the vaccine was well tolerated and increased time to disease progression and survival significantly, compared with historical controls. For more information about the study, call 908-454-7120, ext 324.
